ANTIANTIIDIOTYPIC RESPONSE AND CLINICAL COURSE OF THE DISEASE IN PATIENTS WITH MALIGNANT-MELANOMA IMMUNIZED WITH MOUSE ANTIIDIOTYPIC MONOCLONAL-ANTIBODY MK2-23
ANTIANTIIDIOTYPIC RESPONSE AND CLINICAL COURSE OF THE DISEASE IN PATIENTS WITH MALIGNANT-MELANOMA IMMUNIZED WITH MOUSE ANTIIDIOTYPIC MONOCLONAL-ANTIBODY MK2-23
复制标题
DOI：
10.1089/hyb.1995.14.175
复制
发表时间：
1995-04-01
期刊：
影响因子：
--
通讯作者：
FERRONE, S
中科院分区：
文献类型：
--
作者：
MITTELMAN, A;WANG, XH;FERRONE, S
已利用小鼠抗 id MAb MK2-23 在恶性黑色素瘤患者中实施了主动特异性免疫治疗试验。后者具有抗 HMW-MAA MAb 763.74 决定簇的内部图像。抗-id MAb MK2-23 的免疫原性通过与载体缀合并与佐剂一起施用而增强。抗-id MAb MK2-23在约60%的免疫患者中诱导了体液抗-HMW-MAA免疫。后者与统计学上显着的生存延长相关。这表明抗HMW-MAA免疫可能通过抑制HMW-MAA在黑色素瘤细胞生物学中的功能而对疾病的临床病程产生有益的影响。
An active specific immunotherapy trial has been implemented in patients with malignant melanoma utilizing the mouse anti-id MAb MK2-23. The latter bears the internal image of the determinant by the anti-HMW-MAA MAb 763.74. The immunogenicity of anti-id MAb MK2-23 is enhanced by conjugation to a carrier and administration with an adjuvant. Anti-id MAb MK2-23 induced humoral anti-HMW-MAA immunity in about 60% of the immunized patients. The latter was associated with a statistically significant survival prolongation. It is suggested that anti-HMW-MAA immunity may have a beneficial effect on the clinical course of the disease by inhibiting the function of HMW-MAA in the biology of melanoma cells.